ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Clopidogrel

Also written as “clopidogrel”, “clopidogrel (SR25990C)” and “Clopidogrel (SR25990)”.

Its studies are mostly in Coronary Artery Disease · Cardiovascular Diseases · Acute Coronary Syndrome · Heart Defects, Congenital · Diabetes Mellitus, Type 2, led by 17 companies.

Drug pageClopidogrel: every studyMany companies study it; this page follows only the 55 they lead. All 341 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Feb 23, 200655 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi250 open or runningphase 4since Feb 23, 2006Dec 20, 2002none ahead
Dr. Reddy's Laboratoriesits history only40 open or runningphase 1since Jan 6, 2012Jan 6, 2012none ahead
AstraZenecaits history only30 open or runningphase 1since Jun 4, 2010Jun 4, 2010none ahead
Bristol-Myers Squibbits history only30 open or runningphase 1since Jul 8, 2009Jul 8, 2009none ahead
Eli Lillyits history only30 open or runningphase 2since Jul 26, 2006Jul 26, 2006none ahead
Viatrisits history only30 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
Johnson & Johnsonits history only20 open or runningphase 2since Nov 13, 2014Nov 13, 2014none ahead
Les Laboratoires des Médicaments Stérilesits history only20 open or runningphase 4since Aug 25, 2011Aug 25, 2011none ahead
Merckits history only20 open or runningphase 1since Nov 10, 2009Nov 10, 2009none ahead
Accumetricsits history only10 open or runningno phasesince Mar 24, 2008Mar 24, 2008none ahead

Also a collaborator on its studies: Bayer and Daiichi Sankyo.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sanofi only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Dec 20, 2002.

  1. Oct 20, 2005Phase 3 study in Atrial FibrillationNCT00243178 · 6,706 enrolled · United States, Australia, Austria and more
  2. Nov 4, 2005Phase 3 study in Atrial FibrillationNCT00249873 · 7,554 enrolled · United States, Argentina, Australia and more
  3. Feb 23, 2006Phase 4 study in Metabolic SyndromeNCT00296803 · 216 enrolled · United States
  4. May 11, 2006Phase 3 study in Platelet Aggregation InhibitorsNCT00325390 · 800 enrolled · Japan
  5. Jun 8, 2006Phase 3 study in Angina, UnstableNCT00335452 · 25,086 enrolled · United States, Argentina, Australia and more
  6. Aug 3, 2006Phase 2 study in IschemiaNCT00360386 · 110 enrolled
  7. Oct 10, 2006Phase 4 study in Cerebral InfarctionNCT00386191 · 1,110 enrolled · Japan
  8. Nov 7, 2006Phase 3 study in Heart Defects, CongenitalNCT00396877 · 906 enrolled · United States, Argentina, Belgium and more
  9. Mar 28, 2008Phase 4 study in Peripheral Arterial DiseaseNCT00648453 · 39 enrolled · Hungary
  10. Jul 10, 20082 phase 3 studiesNCT00714961, NCT00716924
  11. Dec 23, 2008Phase 4 study in StrokeNCT00814268 · 358 enrolled · Korea, Republic of
  12. Jan 13, 20092 phase 3 studiesNCT00821834, NCT00833703
  13. Mar 9, 2009Phase 3 study in Peripheral Arterial DiseaseNCT00862420 · 431 enrolled · Japan
  14. May 12, 20107 phase 1 studies in HealthyNCT01123824, NCT01129427, NCT01129414 and 4 more

TargetBeta

P2RY12 →read by rule
“Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 antagonist; Purinergic receptor P2Y12 antagonist”ChEMBL 37, by rule

Other programs on P2RY12

ProgramCompanyFurthest phaseStudies
TicagrelorruleAstraZenecaphase 447
selatogrelruleViatrisphase 311

Studies

All 25 Sanofi leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01129427Healthy · United States1CompletedNov 200966
NCT01129414Healthy · United States1CompletedAug 200972
NCT01129388Healthy · United States1CompletedMay 200972
NCT01129375Healthy · United States1CompletedMay 200972
NCT01129271Healthy · United States, France1CompletedJun 200972
NCT01129063Healthy · France1CompletedMay 200932
NCT01123824Healthy · Germany1CompletedAug 200940
NCT00862420Peripheral Arterial Disease · Japan3CompletedMay 2011431
NCT00833703Heart Defects, Congenital · United States, Brazil, France and more3CompletedJul 201049
NCT00821834Angina, Stable · Japan3CompletedAug 20101,003
NCT00814268Stroke · Korea, Republic of4CompletedMay 2012358
NCT00716924Thrombosis · Mexico3CompletedFeb 2006155
NCT00714961Acute Coronary Syndrome · United States, Argentina, Australia and more3CompletedJan 20053,491
NCT00648453Peripheral Arterial Disease · Hungary4Completed39
NCT00396877Heart Defects, Congenital · United States, Argentina, Belgium and more3CompletedFeb 2010906
NCT00386191Cerebral Infarction · Japan4CompletedDec 20081,110
NCT00360386Ischemia2CompletedFeb 2005110
NCT00335452Angina, Unstable · United States, Argentina, Australia and more3CompletedSep 200925,086
NCT00325390Platelet Aggregation Inhibitors · Japan3Completed800
NCT00296803Metabolic Syndrome · United States4Completed216
NCT00249873Atrial Fibrillation · United States, Argentina, Australia and more3CompletedMar 20097,554
NCT00243178Atrial Fibrillation · United States, Australia, Austria and more3TerminatedSep 20056,706
NCT00174759Arterial Occlusive Diseases · Australia, Austria, Belgium and more3Completed1,460
NCT00115375Heart Defects, Congenital · United States, Belgium, Canada and more2Completed92
NCT00050817Arteriosclerosis · United States, Argentina, Australia and more3Completed15,603

How it is read

Names in the registry

  • “Clopidogrel”, 41 entries
  • “clopidogrel”, 11 entries
  • “clopidogrel (SR25990C)”, 4 entries
  • “Clopidogrel (SR25990)”, 3 entries
  • “clopidogrel (SR25990)”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.